Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is CanSino Biologics' investigational **DTcP-Hib-MCV4 combined vaccine**, an adsorbed pediatric combination vaccine containing diphtheria, tetanus, and tricomponent acellular pertussis antigens; a *Haemophilus influenzae* type b conjugate component; and quadrivalent meningococcal conjugate components covering *Neisseria meningitidis* serogroups A, C, W135, and Y. It is intended to induce active protective immunity against pertussis, diphtheria, tetanus, Hib-associated disease, and meningococcal meningitis caused by the included serogroups. CanSino initiated a Phase I trial in children aged 2 months to 6 years to assess safety and immunogenicity. ([cpivc.com](https://www.cpivc.com/en/newsdel/id/12.html))
- Other names
- DTaP-Hib-MCV4 combined vaccineDTaP-Hib-MCV-4 combined vaccineDTaP-Hib-MCV 4 combined vaccineDTcP-Hib-MCV4 combined vaccineDTcP-Hib-MCV-4 combined vaccineDTcP-Hib-MCV 4 combined vaccinediphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine
02
Targets
Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)FHA (Filamentous hemagglutinin)Diphtheria toxinPRNP (Cellular Prion Protein)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)PRN (Pertactin)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine.